文献速递痛风与晶体性关节病

别嘌醇降尿酸对年轻成人血压影响的随机交叉试验

Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
PubMed 文献 · Arthritis Rheumatol · 2021-06-05

意向性分析显示别嘌醇未降低收缩压,但血流介导舒张(FMD)改善,hsCRP无变化,无严重不良事件;不支持降尿酸治疗年轻成人高血压。

要点

  • 别嘌醇降尿酸未降低年轻成人收缩压。
  • 别嘌醇改善FMD但未改变hsCRP水平。
  • 无严重不良事件,但不支持降尿酸治疗高血压。

核心结论

  • 与安慰剂相比,别嘌醇降尿酸治疗未降低年轻成人收缩压或hsCRP水平,尽管FMD改善。
  • 这些发现不支持将降尿酸作为年轻成人高血压的治疗手段。

研究设计与样本

  • 单中心、随机、双盲、交叉临床试验。
  • 排除慢性肾病、痛风或既往使用降尿酸治疗者。
  • 参与者接受口服别嘌醇300 mg每日或安慰剂1个月,洗脱2-4周后交叉。
  • 82例完成所有访视;平均年龄28.0±7.0岁,62.6%为男性,40.4%为非裔美国人。

主要发现

  • 意向性分析中,别嘌醇治疗期收缩压变化为-1.39±1.16 mmHg,安慰剂期为-1.06±1.08 mmHg。
  • 别嘌醇治疗期FMD较安慰剂期增加(2.5±0.55% vs -0.1±0.42%,P<0.001)。
  • hsCRP水平无变化,无严重不良事件。

临床怎么用

  • 对于年轻成人高血压患者,不应仅基于降尿酸目的使用别嘌醇来降低血压。
  • 别嘌醇可能改善内皮功能(FMD),但此获益未转化为血压下降,需结合个体情况评估。

局限性

  • 治疗期仅1个月,长期效应未知。
  • 研究对象为特定血尿酸阈值的年轻成人,结果不能外推至其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether serum urate reduction with allopurinol lowers blood pressure (BP) in young adults and the mechanisms mediating this hypothesized effect. METHODS: We conducted a single-center, randomized, double-blind, crossover clinical trial. Adults ages 18-40 years with baseline systolic BP ≥120 and <160 mm Hg or diastolic BP ≥80 and <100 mm Hg, and serum urate ≥5.0 mg/dl for men or ≥4.0 mg/dl for women were enrolled. Main exclusion criteria included chronic kidney disease, gout, or past use of urate-lowering therapies. Participants received oral allopurinol (300 mg daily) or placebo for 1 month followed by a 2-4 week washout and then were crossed over. Study outcome measures were change in systolic BP from baseline, endothelial function estimated as flow-mediated dilation (FMD), and high-sensitivity C-reactive protein (hsCRP) levels. Adverse events were assessed. RESULTS: Ninety-nine participants were randomized, and 82 completed all visits. The mean ± SD age was 28.0 ± 7.0 years, 62.6% were men, and 40.4% were African American. In the primary intent-to-treat analysis, systolic BP did not change during the allopurinol treatment phase (mean ± SEM -1.39 ± 1.16 mm Hg) or placebo treatment phase (-1.06 ± 1.08 mm Hg). FMD increased during allopurinol treatment periods compared to placebo treatment periods (mean ± SEM 2.5 ± 0.55% versus -0.1 ± 0.42%; P < 0.001). There were no changes in hsCRP level and no serious adverse events. CONCLUSION: Our findings indicate that urate-lowering therapy with allopurinol does not lower systolic BP or hsCRP level in young adults when compared with placebo, despite improvements in FMD. These findings do not support urate lowering as a treatment for hypertension in young adults.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Gaffo AL, Calhoun DA, Rahn EJ, et al. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021. PMID: 33779064. doi:10.1002/art.41749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。